Business Context and Reporting Period
This Form 6-K, dated September 5, 2023, reports on Novartis AG's announcement regarding the proposed spin-off of its Generics and Biosimilars business, Sandoz. The filing includes a supplement to Sandoz's Listing Prospectus containing financial statements for the first half of 2023 (H1 2023). An Extraordinary General Meeting (EGM) is scheduled for September 15, 2023, to seek shareholder approval for the transaction, with the spin-off planned to occur on or around October 4, 2023.
Key Financial Metrics (Sandoz H1 2023)
- Net Sales: USD 4.8 billion (up 5% reported; up 8% constant currency).
- Sales Drivers: Volume contributed 12 percentage points to growth, offsetting a 4 percentage point negative impact from pricing.
- Core EBITDA: USD 1.0 billion (down 4% reported; up 3% constant currency).
- Regional Performance: Sales growth was primarily driven by Europe, supported by strong volume from prior year launches, a strong cough and cold season, and the Biosimilars business.
Material Changes and Transaction Details
The primary material change is the proposed 100% spin-off of Sandoz. Upon shareholder approval, Novartis shareholders will receive one Sandoz share for every five Novartis shares, and Novartis ADR holders will receive one Sandoz ADR for every five Novartis ADRs. The transaction is expected to be tax-neutral for Swiss tax and US federal income tax purposes. Sandoz is planned to be listed on the SIX Swiss Exchange with a US ADR program, though the ADRs will not be listed on a US national securities exchange.
Guidance, Outlook, and Risks
Guidance and Outlook: Sandoz has confirmed its full-year 2023 guidance and mid-term outlook (2024-2028). The company expects mid-single digit net sales growth for 2023 and the mid-term. Core EBITDA margins are anticipated to expand to 24-26% in the mid-term, up from 18-19% in 2023.
Risks and Contingencies: Completion of the spin-off is subject to conditions including necessary listing approvals, no material adverse changes, and no events outside Novartis's control preventing the transaction. There is no assurance regarding the ultimate timing or completion of the deal. Risks include potential failure to realize strategic synergies, difficulties in separating operations, regulatory delays, and general market uncertainties.
Investor Verification Checklist
- Verify the outcome of the Novartis Extraordinary General Meeting on September 15, 2023, regarding shareholder approval of the spin-off.
- Confirm the final listing date and trading symbol for Sandoz on the SIX Swiss Exchange and the US ADR program.
- Review the full Listing Prospectus supplement for detailed pro forma financial statements and risk factors.
- Monitor for any regulatory approvals required for the separation of the Sandoz business.
- Assess the tax implications for specific investor jurisdictions beyond the stated Swiss and US federal neutrality.